{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:28:00Z","timestamp":1771334880234,"version":"3.50.1"},"reference-count":61,"publisher":"Croatian Society for Medical Biochemistry and Laboratory Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochem. med. (Online)"],"published-print":{"date-parts":[[2026,2,15]]},"abstract":"<jats:p>Tight junctions (TJs) are essential for preserving cell polarity and controlling permeability. It has been disclosed that TJ proteins, especially specific claudins (CLDNs), are linked to inflammation and contribute to the emergence of diverse cancers, including brain malignancies. Aggressive gliomas, including glioblastoma multiforme (GBM), remain among the most common and deadly central nervous system (CNS) tumors worldwide, despite considerable advances in diagnostic and therapeutic approaches. These types of tumors are characterized by high rates of recurrence and metastasis, resulting in poor outcomes and prognosis. The pathophysiology of brain cancer is closely linked to CLDNs, as these specific proteins play critical roles in tumor cell proliferation, invasion, and disruption of the blood-brain barrier (BBB). Some studies reported the potential role of CLDNs in glioma progression and other neurological disorders. The purpose of this review is to highlight the significance of CLDNs in CNS tumors, especially their participation in the formation of malignant gliomas. Additionally, the diagnostic and prognostic importance of selected CLDNs has been assessed. Selected CLDNs, such as CLDN3 and CLDN4 promote GBM growth, proliferation and migration. Moreover, overexpression of CLDN3 support progression and metastasis of these malignancies, while reduced expression of CLDN1 and CLDN5 is observed in advanced gliomas. Presented results suggest that CLDNs may serve as biomarkers for diagnosis and prognosis as well as therapeutic targets in CNS tumors. Further investigation is essential to clarify their clinical relevance and therapeutic potential.<\/jats:p>","DOI":"10.11613\/bm.2026.010501","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:28:07Z","timestamp":1765542487000},"page":"19-31","source":"Crossref","is-referenced-by-count":0,"title":["Claudins proteins in brain tumors"],"prefix":"10.11613","volume":"36","author":[{"given":"Barbara","family":"Mroczko","sequence":"first","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland, Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrianna","family":"Romanowicz","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland, Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"\u0141ukaszewicz-Zaj\u0105c","sequence":"additional","affiliation":[{"name":"Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4885","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"key20251212122802_r1","doi-asserted-by":"crossref","first-page":"18148","DOI":"10.3390\/ijms140918148","article-title":"Emerging roles of claudins in human cancer.","volume":"14","author":"Kwon","year":"2013","journal-title":"Int J Mol Sci"},{"key":"key20251212122802_r2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031128","article-title":"Visualization and quantitative analysis of reconstituted tight junctions using localization microscopy.","volume":"7","author":"Kaufmann","year":"2012","journal-title":"PLoS One"},{"key":"key20251212122802_r3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.bbamem.2007.10.018","article-title":"Structure and function of claudins.","volume":"1778","author":"Krause","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"key20251212122802_r4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1152\/physrev.00019.2012","article-title":"Claudins and the modulation of tight junction permeability.","volume":"93","author":"G\u00fcnzel","year":"2013","journal-title":"Physiol Rev"},{"key":"key20251212122802_r5","unstructured":"National Center for Biotechnology Information. Available from: http:\/\/www.ncbi.nlm.nih.gov\/. Accessed January 14th 2025."},{"key":"key20251212122802_r6","doi-asserted-by":"crossref","first-page":"C190","DOI":"10.1152\/ajpcell.00074.2013","article-title":"Claudin-2 pore function requires an intramolecular disulfide bond between two conserved extracellular cysteines.","volume":"305","author":"Li","year":"2013","journal-title":"Am J Physiol Cell Physiol"},{"key":"key20251212122802_r7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamem.2020.183344","article-title":"Channel functions of claudins in the organization of biological systems.","volume":"1862","author":"Meoli","year":"2020","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"key20251212122802_r8","article-title":"Claudin and pancreatic cancer.","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"key20251212122802_r9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1248571","article-title":"Crystal structure of a claudin provides insight into the architecture of tight junctions.","volume":"344","author":"Suzuki","year":"2014","journal-title":"Science"},{"key":"key20251212122802_r10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition.","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20251212122802_r11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1124\/mol.112.079798","article-title":"Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter CTR1.","volume":"83","author":"Shang","year":"2013","journal-title":"Mol Pharmacol"},{"key":"key20251212122802_r12","article-title":"Context-dependent roles of claudins in tumorigenesis.","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"key20251212122802_r13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/cancers14020290","article-title":"Claudins and gastric cancer: An overview.","volume":"14","author":"Hashimoto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20251212122802_r14","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.3892\/ijo.2014.2298","article-title":"The expression of claudin 1 correlates with \u03b2-catenin and is a prognostic factor of poor outcome in gastric cancer.","volume":"44","author":"Huang","year":"2014","journal-title":"Int J Oncol"},{"key":"key20251212122802_r15","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.12659\/MSM.904177","article-title":"CLDN1 increases drug resistance of non-small cell lung cancer by activating autophagy via up-regulation of ULK1 phosphorylation.","volume":"23","author":"Zhao","year":"2017","journal-title":"Med Sci Monit"},{"key":"key20251212122802_r16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.bbamcr.2017.12.005","article-title":"Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.","volume":"1865","author":"Maruhashi","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"key20251212122802_r17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.pan.2018.10.009","article-title":"Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer.","volume":"19","author":"Okui","year":"2019","journal-title":"Pancreatology"},{"key":"key20251212122802_r18","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary.","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-oncol"},{"key":"key20251212122802_r19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain malignancies in adults: A review.","volume":"329","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"key20251212122802_r20","first-page":"1423","article-title":"Primary brain tumors in adults.","volume":"77","author":"Chandana","year":"2008","journal-title":"Am Fam Physician"},{"key":"key20251212122802_r21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000095179","article-title":"Evaluation of epidemiologic evidence for primary adult brain tumor risk factors using evidence-based medicine.","volume":"19","author":"Fisher","year":"2006","journal-title":"Prog Neurol Surg"},{"key":"key20251212122802_r22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10143-012-0401-6","article-title":"Exploratory investigation of eight circulating plasma markers in brain tumor patients.","volume":"36","author":"Ilhan-Mutlu","year":"2013","journal-title":"Neurosurg Rev"},{"key":"key20251212122802_r23","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/brain\/awm263","article-title":"Serum GFAP is a diagnostic marker for glioblastoma multiforme.","volume":"130","author":"Jung","year":"2007","journal-title":"Brain"},{"key":"key20251212122802_r24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-012-0874-8","article-title":"Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas.","volume":"109","author":"Husain","year":"2012","journal-title":"J Neurooncol"},{"key":"key20251212122802_r25","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1215\/15228517-2008-005","article-title":"Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.","volume":"10","author":"Kesari","year":"2008","journal-title":"Neuro-oncol"},{"key":"key20251212122802_r26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-006-9225-y","article-title":"A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.","volume":"81","author":"Groves","year":"2007","journal-title":"J Neurooncol"},{"key":"key20251212122802_r27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/030089160709300308","article-title":"Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas.","volume":"93","author":"Quaranta","year":"2007","journal-title":"Tumori"},{"key":"key20251212122802_r28","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-6-186","article-title":"The claudin gene family: Expression in normal and neoplastic tissues.","volume":"6","author":"Hewitt","year":"2006","journal-title":"BMC Cancer"},{"key":"key20251212122802_r29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1073\/pnas.96.2.511","article-title":"Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands.","volume":"96","author":"Morita","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20251212122802_r30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.0303-6987.2005.00324.x","article-title":"Loss of claudin-1 expression in tumor-associated vessels correlates with acquisition of metastatic phenotype in melanocytic neoplasms.","volume":"32","author":"Cohn","year":"2005","journal-title":"J Cutan Pathol"},{"key":"key20251212122802_r31","first-page":"139","article-title":"Decreased expression of claudin-1 correlates with recurrence status in breast cancer.","volume":"20","author":"Morohashi","year":"2007","journal-title":"Int J Mol Med"},{"key":"key20251212122802_r32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3390\/ijms21020569","article-title":"Claudin-1, a double-edged sword in cancer.","volume":"21","author":"Bhat","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20251212122802_r33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2174\/1871527313666141023121550","article-title":"Downregulated expression of claudin-1 and claudin-5 and upregulation of \u03b2-catenin: Association with human glioma progression.","volume":"13","author":"Karnati","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key20251212122802_r34","doi-asserted-by":"crossref","first-page":"17440","DOI":"10.1038\/s41598-022-22156-6","article-title":"Claudin-3 inhibits tumor-induced lymphangiogenesis via regulating the PI3K signaling pathway in lymphatic endothelial cells.","volume":"12","author":"Lei","year":"2022","journal-title":"Sci Rep"},{"key":"key20251212122802_r35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clinre.2018.11.014","article-title":"Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease.","volume":"43","author":"Wang","year":"2019","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"key20251212122802_r36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12032-023-02136-0","article-title":"Claudin-3 facilitates the progression and mediates the tumorigenic effects of TGF-\u03b2 in glioblastoma multiforme.","volume":"40","author":"Sun","year":"2023","journal-title":"Med Oncol"},{"key":"key20251212122802_r37","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jconrel.2020.04.006","article-title":"Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems.","volume":"322","author":"Xu","year":"2020","journal-title":"J Control Release"},{"key":"key20251212122802_r38","first-page":"2530","article-title":"Claudin 4 enhances the malignancy of glioma cells via NNAT\/Wnt signaling.","volume":"13","author":"Yang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"key20251212122802_r39","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-022-04788-8","article-title":"TGF-\u03b2 induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-\u03b1\/NF-\u03baB signal pathway.","volume":"13","author":"Yan","year":"2022","journal-title":"Cell Death Dis"},{"key":"key20251212122802_r40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1111\/j.1349-7006.2009.01239.x","article-title":"Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.","volume":"100","author":"Suzuki","year":"2009","journal-title":"Cancer Sci"},{"key":"key20251212122802_r41","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.3390\/ijms24065494","article-title":"Claudin-4: A new molecular target for epithelial cancer therapy.","volume":"24","author":"Fujiwara-Tani","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20251212122802_r42","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/cns.12764","article-title":"Claudin-5 regulates blood-brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis.","volume":"23","author":"Ma","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"key20251212122802_r43","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s004010000180","article-title":"Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme.","volume":"100","author":"Liebner","year":"2000","journal-title":"Acta Neuropathol"},{"key":"key20251212122802_r44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/NEN.0b013e31816fd622","article-title":"Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor-\u03b22 involves matrix metalloproteinases and tight junction proteins.","volume":"67","author":"Ishihara","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"key20251212122802_r45","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/j.2040-4603.2012.tb00450.x","article-title":"Claudins and other tight junction proteins.","volume":"2","author":"G\u00fcnzel","year":"2012","journal-title":"Compr Physiol"},{"key":"key20251212122802_r46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/dvdy.1174","article-title":"Claudin-6: A novel tight junction molecule is developmentally regulated in mouse embryonic epithelium.","volume":"222","author":"Turksen","year":"2001","journal-title":"Dev Dyn"},{"key":"key20251212122802_r47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"key":"key20251212122802_r48","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/ncomms2992","article-title":"Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells.","volume":"4","author":"Ben-David","year":"2013","journal-title":"Nat Commun"},{"key":"key20251212122802_r49","article-title":"Identification of Claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis.","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20251212122802_r50","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.21873\/anticanres.16580","article-title":"Claudin-10 in the blood brain barrier function of cerebral endothelial cells and transendothelial invasion of breast cancer cells.","volume":"43","author":"Zhuang","year":"2023","journal-title":"Anticancer Res"},{"key":"key20251212122802_r51","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1530\/JME-18-0055","article-title":"Integrated omics: tools, advances and future approaches.","volume":"62","author":"Misra","year":"2019","journal-title":"J Mol Endocrinol"},{"key":"key20251212122802_r52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ebiom.2019.05.054","article-title":"Discovery and validation of temporal patterns involved in human brain ketometabolism in cerebral microdialysis fluids of traumatic brain injury patients.","volume":"44","author":"Eiden","year":"2019","journal-title":"EBioMedicine"},{"key":"key20251212122802_r53","first-page":"16772","article-title":"New diagnostic technologies in laboratory medicine: potential benefits and challenges.","volume":"134","author":"Nagler","year":"2024","journal-title":"Pol Arch Intern Med"},{"key":"key20251212122802_r54","article-title":"Machine learning applications in precision medicine: from metabolic phenotyping to clinical practice.","volume":"179","author":"Nilius","year":"2024","journal-title":"Trends Analyt Chem"},{"key":"key20251212122802_r55","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1007\/s00432-021-03725-0","article-title":"Claudins as biomarkers of differential diagnosis and prognosis of tumors.","volume":"147","author":"Popova","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"key20251212122802_r56","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s43046-022-00125-4","article-title":"Potential roles of claudin-3 and claudin-4 ovarian cancer management.","volume":"34","author":"Uthayanan","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"key20251212122802_r57","first-page":"3406","article-title":"Targeting claudins in cancer: diagnosis, prognosis and therapy.","volume":"11","author":"Li","year":"2021","journal-title":"Am J Cancer Res"},{"key":"key20251212122802_r58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jss.2019.04.048","article-title":"Anti-claudin-1 conjugated to a near-infrared fluorophore targets colon cancer in PDxO mouse models.","volume":"242","author":"Hollandsworth","year":"2019","journal-title":"J Surg Res"},{"key":"key20251212122802_r59","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/CCO.0000000000001041","article-title":"State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.","volume":"36","author":"Rogers","year":"2024","journal-title":"Curr Opin Oncol"},{"key":"key20251212122802_r60","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER-2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomized, double-blind, phase 3 trial.","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"key20251212122802_r61","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CapeOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"}],"container-title":["Biochemia medica"],"original-title":[],"link":[{"URL":"https:\/\/biochemia-medica.com\/en\/journal\/36\/1\/10.11613\/BM.2026.010501\/fullArticle","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:42:16Z","timestamp":1771332136000},"score":1,"resource":{"primary":{"URL":"https:\/\/biochemia-medica.com\/en\/journal\/36\/1\/10.11613\/BM.2026.010501"}},"subtitle":["expression patterns and therapeutic target"],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,17]]},"published-print":{"date-parts":[[2026,2,15]]}},"URL":"https:\/\/doi.org\/10.11613\/bm.2026.010501","relation":{},"ISSN":["1846-7482","1330-0962"],"issn-type":[{"value":"1846-7482","type":"electronic"},{"value":"1330-0962","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}